Levosimendan: Ph III LEVO-CTS data

Top-line data from the double-blind, North American Phase III LEVO-CTS trial in about 880 patients undergoing coronary artery bypass graft (CABG) surgery or mitral valve surgery who are at risk

Read the full 301 word article

User Sign In